Walgreen Does it Right

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

The market has been relentless in punishing stocks that miss expectations, whether it's due to blizzards on the East Coast or more internal factors. Walgreen (NASDAQ: WBA  ) , though, can apparently do no wrong. The drug store chain this week missed quarterly profit expectations, yet shares still rallied as Walgreen did achieve record sales and a record number of prescriptions filled. Walgreen and its peers have a perennial wind at their backs with more people taking more medication all the time. One of the big keys to keeping investors and analysts happy has been improving the front of the store, where margins are lower but retail space abounds. Is Walgreen as desirable as the market thinks?

Solid quarter
Sales climbed slightly more than 5% to a record $19.6 billion in Walgreen's fiscal 2014 second quarter, driven largely by an appetizing 4.3% climb in same-store sales. These are especially promising figures, as many retailers took a hit due to weather conditions in recent months, and the recurring patent cliff (in which branded drugs become generic ones -- a great turn for drug stores given the higher profit margins of generics) is at a sluggish point, keeping additional margin pressure on prescriptions.

Like many private label versus branded goods, retailers purchase generic pharmaceuticals at a much lower price than their Pfizer, Merck, and other major drug-maker counterparts. The drugs, which can be sold at much lower costs to the consumer, often see increased demand.

The bottom line felt the margin pressures, as earnings dropped an adjusted 5.2% to $0.91 per share. For one thing, the patent cliff was at a peak in the first quarter of last year, making this year an especially difficult comp in addition to being a low point in the cycle. Why would last year's first quarter affect this year's second?--The peak of last year's Q1 carried sales higher through Q2. 

The market didn't care, and appropriately so. Walgreen has plenty of long-term bullish indicators to make the year-over-year drop a nonevent. The patent cliff situation should cycle back into positive territory by the last leg of 2014. In the meantime, Walgreen is keeping costs controlled and continuing to focus on increasing the profitability of the front of store. Front-end comps were up 2% in the recent quarter, which again reinforces the effort in light of extreme weather. Average basket sizes are increasing, and the company is capturing greater market share in the daily living category.

Anything not to like?
From an operational and managerial point of view, Walgreen leaves little on the table. The company's retail pharmacy market share is nearly 20%. Its stake in European pharmacy juggernaut Alliance Boots (a $6.7 billion deal sealed midway through 2013) is on track to deliver better synergies than previously thought.

Interestingly, the company intends to close 76 locations throughout the year. For a company whose strategy is basically to have stores on every corner in America, it's refreshing to see some attention to store-level performance. Management noted that it was looking over density data, real estate positioning, and trends in the stores' immediate areas. Despite its 8,000+ retail footprint, the company seems to have its finger on the pulse of each individual store.

At 17 times earnings, investors aren't getting a bargain on shares, but they are buying a company with great long-term potential. At the current level, Walgreen stock has its fair share of downside risk, but growth seekers should pay close attention. This is one of an increasingly few brick-and-mortar businesses that is only going up.


6 stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.


Read/Post Comments (2) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 28, 2014, at 8:22 PM, skubbydue wrote:

    The fool has it wrong. Under CEO Wasson, the short term profits are present. However, the qualities that have brought the masses to Walgreens with the inflated prices are now gone,

    I was a long time Walgreens customer and investor. I feel under Wasson based on my customer experience and based on other comments, Walgreens has hired the incompetent pharmacy managers, lack customer service so long a trade mark of the company.

    District managers used to respond to customer complaints in person. Now the pharmacist can not pick up the phone to say the problem is corrected.

    Someone explain how quantity 40 for insulin translates into 3 vials. Explain why a call to Express Scripts for approval of 90 pills is resubmitted as 30 pills. Explain why the pharmacist takes more than 1 week to fix a problem she caused and continues her lies.

    The company bought bioscript - my insurance and I contribute $80,000 per month to BioScript.

    Not any more. I am dumping the stock and all my activities with this company. Wasson needs to go..

  • Report this Comment On March 31, 2014, at 1:46 PM, 4Mike4 wrote:

    Uh Skubby...first couple of lines of your post had a legitimate foundation until you turned it into your personal valedictory speech from the Reese Witherspoon School of do you know who I am and how important I am. Your version of this speech is given daily in practically every venue of retail.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2893218, ~/Articles/ArticleHandler.aspx, 9/1/2015 6:44:24 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Michael Lewis

Michael is a value-oriented investment analyst with a specific interest in retail and media businesses. Before coming to the Fool, Michael worked with private investment funds focusing on deep value and special situations. Currently living in the media capital of the world--Los Angeles, California.

Today's Market

updated Moments ago Sponsored by:
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,913.85 -58.33 -2.96%
NASD 4,636.11 -140.40 -2.94%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 4:00 PM
WBA $86.04 Down -0.51 -0.59%
Walgreen Boots All… CAPS Rating: ****